A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
Crohn's Disease risankizumab ABBV-066 BI 655066 Crohn Disease Antibodies, Monoclonal Risankizumab IV Risankizumab SC Double-blind Risankizumab Dose 1 (Sub-Study 1) Double-blind Risankizumab Dose 2 (Sub-Study 1) Maintenance Risankizumab Dose 1 (Sub-Study 2) Maintenance Risankizumab Dose 2 (Sub-Study 2) Open-label Risankizumab (Sub-Study 3)
Lead Scientist at UCSF
- Melvin Heyman
Professor, Pediatrics. Authored (or co-authored) 315 research publications.
- accepting new patients by invitation only
- Start Date
- Completion Date
- This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
- Phase 3
- Study Type
- Last Updated